SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase.

SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase.

SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase.

SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase.

SB 203580 is a specific inhibitor of p38?? and p38?? which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27.

SB 203580 is a specific inhibitor of p38?? and p38?? which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27.

SB 203580 is a specific inhibitor of p38?? and p38?? which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27.

SB 203580 is a specific inhibitor of p38?? and p38?? which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27.

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3?? with an IC50 value of 34 nM (similar potency for GSK3??).

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3?? with an IC50 value of 34 nM (similar potency for GSK3??).

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3?? with an IC50 value of 34 nM (similar potency for GSK3??).

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3?? with an IC50 value of 34 nM (similar potency for GSK3??).

SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively)

SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively)

SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively)

SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

SB 334867 is a selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.

SB 334867 is a selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.

SB 334867 is a selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.

SB 334867 is a selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.

SB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.

SB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.

SB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.

SB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.

SB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .

SB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .

SB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .

SB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .

SB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells

SB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells

SB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells

SB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells

SB 743921, a second generation KSP inhibitor, is a highly potent and active therapeutic in preclinical models of cancer.

SB 743921, a second generation KSP inhibitor, is a highly potent and active therapeutic in preclinical models of cancer.